Although patients with MM receiving anti-BCMA CAR T-cell therapy may have a different CV risk profile than patients with leukemia or lymphoma requiring CAR T-cell therapy (e.g., prior anthracycline exposure), the risk of CV toxicity mediated by the physiological stress of CRS remains. This evidence concerns the gene TNFRSF17 and leukemia.